Avencia Sánchez-Mejías receives Women and Leadership Award
Dr Avencia Sánchez-Mejías, co-founder and CEO of Integra Therapeutics, won the first edition of the Women and Leadership Award promoted by Deusto Business School, Cinco Días and Banco Santander to boost and raise awareness of the talent of female executives at companies and in entrepreneurship. The ceremony was held on 2 June at the business […]
Integra Therapeutics appoints Mark Bonyhadi as new independent director
Integra Therapeutics announced today that Dr Mark Bonyhadi has been appointed to its Board of Directors as an independent director. Dr Bonyhadi has more than 30 years of experience in biopharmaceutical leadership roles in the US, specifically in developing commercially viable approaches to take cell and gene therapies and regenerative medicine from the lab to […]
Integra Therapeutics completes the €6-million seed round with the addition of Columbus Venture Partners
Integra Therapeutics has closed an additional €1.5-million investment from venture capital firm Columbus Venture Partners. This investment comes on top of the €4.5 million Integra Therapeutics raised last December from AdBio Partners, Invivo Capital and Takeda Ventures and completes its seed round in line with the company’s set goals. The new funds will go to […]
Integra Therapeutics appoints recognized geneticist George Church to its Scientific Advisory Board
Integra Therapeutics announced today the appointment of Professor George Church to its Scientific Advisory Board (SAB). Prof. George Church is a pioneering scientist in reading and writing DNA. He developed the first direct genomic sequencing method and helped initiate the Human Genome Project in 1984 and the Personal Genome Project in 2005 and demonstrated that […]
Integra Therapeutics at ‘CRISPR News Medicine’
CRISPR News Medicine publishes an article entitled Adaptation of jumping gene boosts CRISPR-Cas gene-writing technology to new heights about new FiCAT platform developed by Integra Therapeutics. By Henri van de Vrugt
Integra Therapeutics at ‘Pharmaceutical Technology’
Pharmaceutical Technology review publishes an article entitled Integra Therapeutics Q&A: building next-generation gene editing tools where our CEO Avencia Sánchez-Mejías discusses how the company’s gene writing tool could improve advanced therapies for patients. By Darcy Jimenez
